Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs

Author:

Mori Daiki1,Kimoto Emi2,Rago Brian2,Kondo Yusuke1,King‐Ahmad Amanda2,Ramanathan Ragu2,Wood Linda S.3,Johnson Jillian G.3,Le Vu H.4,Vourvahis Manoli5,David Rodrigues A.2,Muto Chieko6,Furihata Kenichi7,Sugiyama Yuichi8,Kusuhara Hiroyuki1

Affiliation:

1. Laboratory of Molecular Pharmacokinetics Graduate School of Pharmaceutical Sciences The University of Tokyo Tokyo Japan

2. ADME Sciences, Medicine Design Pfizer Inc. Groton Connecticut USA

3. Clinical Pharmacogenomics Lab Early Clinical Development Pfizer Inc. Groton Connecticut USA

4. Biostatistics Pfizer Inc. Collegeville PA USA

5. Clinical Pharmacology Pfizer Inc. New York New York USA

6. Pfizer Inc. Tokyo Japan

7. P‐One Clinic Keikokai Medical Corp Tokyo Japan

8. RIKEN Innovation Center Research Cluster for Innovation RIKEN Kanagawa Japan

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Cited by 67 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3